Christopher M. Hocking

1.1k citations
20 papers · 827 · 2 hit papers · h-index 8

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies
  • Surgery top 10%
    • Bladder and Urothelial Cancer Treatments
    • Nausea and vomiting management

Papers in

    • Colorectal Cancer Treatments and Studies 7
    • Neutropenia and Cancer Infections 1
    • Global Cancer Incidence and Screening 1
    • Cancer Immunotherapy and Biomarkers 1
    • Cancer survivorship and care 1
    • Renal cell carcinoma treatment 4

Christopher M. Hocking

18 papers receiving 811 citations

Christopher M. Hocking's Hit Papers

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial 2022 · 235 citations
2350+2+4Years since publication100200300400

Peers

Christopher M. Hocking
Comparison fields: 5 of 49
  • Oncology 302
  • Surgery 301
  • Pulmonary and Respiratory Medicine 206
  • Cancer Research 22
  • Statistics and Probability 16
Replace Sundeep Agrawal with:
Sundeep Agrawal United States
Niels Viggo Jensen Denmark
Luis Eduardo Rosa Zucca Brazil
János Révész Hungary
Cinzia Baldessari Italy
Taketoshi Nara Japan
Esther van Meerten Netherlands
Linda Cerbone Italy
I Grossmann Netherlands
Hiroaki Kikukawa Japan
Christopher M. Hocking relative to Sundeep Agrawal United States Sundeep Agrawal's profile →
Citations per field
00.5×2×2.8×
Sundeep Agrawal · 1×
Citations per year

Countries citing papers authored by Christopher M. Hocking

Since Specialization
Citations

This map shows the geographic impact of Christopher M. Hocking's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher M. Hocking with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher M. Hocking more than expected).

Fields of papers citing papers by Christopher M. Hocking

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher M. Hocking. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher M. Hocking. The network helps show where Christopher M. Hocking may publish in the future.

Co-authors

The 25 scholars most cited alongside Christopher M. Hocking, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher M. Hocking Line = papers co-authored together Christopher M. Hocking links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Hit paper breakdown →
2020408
2
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
Hit paper breakdown →
2022235
3 201455
4 201331
5 202427
6 201322
7 201410
8 20139
9 20148
10 20225
11 20134
12 20234
13 20153
14 20242
15 20141
16 20211
17 20221
18 20241
19 20250
20 20260

About Christopher M. Hocking

Christopher M. Hocking is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Health, Surgery and Pathology and Forensic Medicine, having authored 20 papers that have together received 827 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (7 papers), Renal cell carcinoma treatment (4 papers), Neutropenia and Cancer Infections (1 paper), Global Cancer Incidence and Screening (1 paper), Nausea and vomiting management (1 paper), Economic and Financial Impacts of Cancer (1 paper), Cancer Immunotherapy and Biomarkers (1 paper) and Cancer survivorship and care (1 paper). The work is most often cited by research in Oncology (302 citations), Surgery (301 citations), Pulmonary and Respiratory Medicine (206 citations), Cancer Research (22 citations) and Statistics and Probability (16 citations). Christopher M. Hocking has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Ganessan Kichenadasse, Timothy Jay Price, Toni K. Choueiri, Thomas B. Powles, Burçin Şimşek, Howard Gurney, Andrea Borghese Apolo, Elizabeth Riley Kessler, Amishi Yogesh Shah and Joshua H. Zhang. Their work appears in journals such as The Lancet Oncology, The Lancet, The Medical Journal of Australia, Supportive Care in Cancer and BMC Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact